Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177 Lu-DOTATATE

We report the impact of Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial ( Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], = 117; high-dose octreotide LAR, = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures. Patients (intent-to-treat) who received Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 days per 4 weeks, respectively, compared with 0.99, 1.44, and 2.54 days for high-dose octreotide LAR. The mean differences were 3.11 days (95% confidence interval, 1.35-4.88; = 0.0007) for abdominal pain, 3.11 days (1.18-5.04; = 0.0017) for diarrhea, and 1.98 days (0.08-3.88; = 0.0413) for flushing, favoring Lu-DOTATATE. A positive repeated measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing. In addition to efficacy and quality of life benefits, symptom diaries from NETTER-1 demonstrated that treatment with Lu DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut NETs, compared with high-dose octreotide LAR, supporting a beneficial effect of Lu DOTATATE on HRQoL.